Matthew J Damasiewicz1, Thomas L Nickolas. 1. Department of Nephrology, Monash Health Department of Medicine, Monash University, Clayton, Victoria, Australia Division of Nephrology, Department of Medicine, Columbia University Medical Center, New York, New York, USA.
Abstract
PURPOSE OF REVIEW: Chronic kidney disease (CKD) is associated with the development of mineral and bone disorders (MBD), including renal osteodystrophy (ROD). ROD is a global disorder of bone strength that is associated with an increased fracture risk. The use of bisphosphonates for fracture risk reduction in CKD remains controversial. This review provides a synopsis of the state-of-the literature regarding the safety and potential antifracture benefits of bisphosphonates in CKD patients. RECENT FINDINGS: In preclinical studies of animals with CKD 3-4 and evidence of CKD-MBD, bisphosphonates resulted in changes in bone quality that improve bone strength. Bone turnover was generally reduced to a similar extent in animals with and without CKD. Post hoc analyses of randomized trials in patients with CKD 3-4 reported increases in bone mineral density (BMD) and fracture reduction that were similar in patients with and without CKD. There are no primary clinical trial data in patients with CKD-MBD. SUMMARY: In patients with CKD without evidence of CKD-MBD, the use of bisphosphonates should follow general population guidelines. The lack of data for patients with CKD 4-5D and evidence of CKD-MBD makes treatment decisions challenging. Clinical studies are urgently needed to provide data on the safety and antifracture benefits of bisphosphonates in these cohorts.
PURPOSE OF REVIEW: Chronic kidney disease (CKD) is associated with the development of mineral and bone disorders (MBD), including renal osteodystrophy (ROD). ROD is a global disorder of bone strength that is associated with an increased fracture risk. The use of bisphosphonates for fracture risk reduction in CKD remains controversial. This review provides a synopsis of the state-of-the literature regarding the safety and potential antifracture benefits of bisphosphonates in CKD patients. RECENT FINDINGS: In preclinical studies of animals with CKD 3-4 and evidence of CKD-MBD, bisphosphonates resulted in changes in bone quality that improve bone strength. Bone turnover was generally reduced to a similar extent in animals with and without CKD. Post hoc analyses of randomized trials in patients with CKD 3-4 reported increases in bone mineral density (BMD) and fracture reduction that were similar in patients with and without CKD. There are no primary clinical trial data in patients with CKD-MBD. SUMMARY: In patients with CKD without evidence of CKD-MBD, the use of bisphosphonates should follow general population guidelines. The lack of data for patients with CKD 4-5D and evidence of CKD-MBD makes treatment decisions challenging. Clinical studies are urgently needed to provide data on the safety and antifracture benefits of bisphosphonates in these cohorts.
Authors: J E Dunford; K Thompson; F P Coxon; S P Luckman; F M Hahn; C D Poulter; F H Ebetino; M J Rogers Journal: J Pharmacol Exp Ther Date: 2001-02 Impact factor: 4.030
Authors: Elizabeth A Swallow; Mohammad W Aref; Corinne E Metzger; Spencer Sacks; Demi R Lehmkuhler; Neal Chen; Max A Hammond; Paul R Territo; Thomas L Nickolas; Sharon M Moe; Matthew R Allen Journal: Bone Date: 2019-07-09 Impact factor: 4.398
Authors: M Ota; M Takahata; T Shimizu; Y Kanehira; H Kimura-Suda; Y Kameda; H Hamano; S Hiratsuka; D Sato; N Iwasaki Journal: Osteoporos Int Date: 2016-12-08 Impact factor: 4.507
Authors: Ian R Reid; Jacques P Brown; Peter Burckhardt; Zebulun Horowitz; Peter Richardson; Ulrich Trechsel; Albert Widmer; Jean-Pierre Devogelaer; Jean-Marc Kaufman; Philippe Jaeger; Jean-Jacques Body; Maria Luisa Brandi; Johann Broell; Raffaele Di Micco; Andrea Riccardo Genazzani; Dieter Felsenberg; Joachim Happ; Michael J Hooper; Jochen Ittner; Georg Leb; Hans Mallmin; Timothy Murray; Sergio Ortolani; Alessandro Rubinacci; Maria Saaf; Goran Samsioe; Leon Verbruggen; Pierre J Meunier Journal: N Engl J Med Date: 2002-02-28 Impact factor: 91.245
Authors: Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings Journal: N Engl J Med Date: 2007-05-03 Impact factor: 91.245
Authors: Stephen B Walsh; Paul Altmann; James Pattison; Martin Wilkie; Muhammad M Yaqoob; Christopher Dudley; Paul Cockwell; Paul Sweny; Linda M Banks; Margaret Hall-Craggs; Kate Noonan; Christopher Andrews; John Cunningham Journal: Am J Kidney Dis Date: 2009-05 Impact factor: 8.860
Authors: K T Smerud; S Dolgos; I C Olsen; A Åsberg; S Sagedal; A V Reisæter; K Midtvedt; P Pfeffer; T Ueland; K Godang; J Bollerslev; A Hartmann Journal: Am J Transplant Date: 2012-09-04 Impact factor: 8.086
Authors: Lisa M Wilson; Casey M Rebholz; Ermias Jirru; Marisa Chi Liu; Allen Zhang; Jessica Gayleard; Yue Chu; Karen A Robinson Journal: Ann Intern Med Date: 2017-04-11 Impact factor: 25.391